Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency

By Sharecast

Date: Friday 19 Dec 2025

Stockholm, Sweden, December 19, 2025. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced that the Company has initiated a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for Emcitate® (tiratricol), its investigational drug for the treatment of MCT8 deficiency.

Emcitate®...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Top of Page